Development of a novel detection technology for drug resistance mutation sites of Mycobacterium tuberculosis using Luminex liquid chip technology

Abstract

Purpose: To develop a novel detection technology for drug-resistance mutation sites of Mycobacterium tuberculosis (MTB) using a Luminex liquid chip.Methods: Using polymerase chain reaction (PCR) amplification and hybridization analysis, MTB infection and drug-resistant mutation sites of the first-line and second-line anti-MTB drugs were simultaneously identified. A novel detection method was applied to analyze the wild-type standard strains of MTB and 33 clinical samples, and the results were compared with Sanger sequencing results for PCR products.Results: It was revealed that the sensitivity (100 %) and specificity (100 %) of the novel detection method for 31 samples were satisfactory, and all mutation sites were correctly detected. Compared with traditional PCR and culture-based drug sensitivity test, the novel detection method increased the speed of identification of drug-resistant TB, reduced clinicians' workload, and decreased treatment cost. Among 31 samples, 12.90 % were resistant to isoniazid (4/31), 35.48 % to rifampicin (11/31), and 12.90 % to ofloxacin (p < 0.05). Furthermore, 2 (6.45 %) samples were resistant to both isoniazid and rifampicin, 2 (6.45 %) samples to both rifampicin and ofloxacin, and 1 (3.22 %) sample to both isoniazid and ofloxacin, and 1 (3.22%) sample to all the three drugs (p < 0.05).Conclusion: Development and wide application of this novel detection method will facilitate the treatment of MTB, thus reducing the spread of drug-resistant MTB, and improving the prevention and treatment of MTB.